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The enzyme 11
 
 
 
–hydroxysteroid dehydrogenase (HSD) type 1 converts inactive cortisone 
into active cortisol in cells, thereby raising the effective glucocorticoid (GC) tone above 
serum levels. We report that pharmacologic inhibition of 11
 
 
 
-HSD1 has a therapeutic 
effect in mouse models of metabolic syndrome. Administration of a selective, potent 
11
 
 
 
-HSD1 inhibitor lowered body weight, insulin, fasting glucose, triglycerides, and 
cholesterol in diet-induced obese mice and lowered fasting glucose, insulin, glucagon, 
triglycerides, and free fatty acids, as well as improved glucose tolerance, in a mouse model 
of type 2 diabetes. Most importantly, inhibition of 11
 
 
 
-HSD1 slowed plaque progression in 
a murine model of atherosclerosis, the key clinical sequela of metabolic syndrome. Mice 
with a targeted deletion of apolipoprotein E exhibited 84% less accumulation of aortic 
total cholesterol, as well as lower serum cholesterol and triglycerides, when treated with an 
11
 
 
 
-HSD1 inhibitor. These data provide the first evidence that pharmacologic inhibition of 
intracellular GC activation can effectively treat atherosclerosis, the key clinical consequence 
of metabolic syndrome, in addition to its salutary effect on multiple aspects of the 
metabolic syndrome itself.
 
Glucocorticoids (GCs) influence a wide variety
of physiologic functions, including immune and
inflammatory responses, stress responses, aspects
of development, and metabolism. Thus, it is
not surprising that the levels of these multipo-
tent hormones are tightly regulated. Secretion
of GCs from the adrenal cortex is controlled
by negative feedback via the hypothalamic-
pituitary-adrenal (HPA) axis. The main regu-
lators of intracellular GC levels are 11
 
 
 
–hydroxy-
steroid  dehydrogenase (HSD) enzymes. Two
isoforms of 11
 
 
 
-HSD have been cloned and
characterized (1, 2). 11
 
 
 
-HSD type 1 is an
NADP(H)-dependent enzyme that acts primarily
as a reductase in intact cells, converting the in-
active 11-keto metabolites cortisone (in humans)
or 11-dehydrocorticosterone (in rodents) into
the active GCs cortisol or corticosterone, re-
spectively. 11
 
 
 
-HSD1 is expressed in most tissue
types and potentiates the action of endogenous
GCs by increasing their local concentration.
11
 
 
 
-HSD type 2 is an NAD(H)-dependent en-
zyme that catalyzes the reverse reaction, oxidiz-
ing active GCs to their inactive 11-keto forms.
Although 11
 
 
 
-HSD1 is widely expressed,
11
 
 
 
-HSD2 expression is limited to tissues that
express the mineralocorticoid receptor, such as
the kidney and gut, as well as to the placenta.
By inactivating cortisol, 11
 
 
 
-HSD2 prevents it
from binding to the mineralocorticoid receptor,
thus conferring aldosterone specificity on the
receptor. In the placenta, the enzyme prevents
maternal GCs from reaching the fetal circulation.
The metabolic syndrome is a cluster of car-
diovascular risk factors, including visceral obesity,
insulin resistance, dyslipidemia, and hyperten-
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sion. It has been noted that the features of metabolic syn-
drome are also seen in patients with increased circulating
GCs, or Cushing’s syndrome. However, patients with meta-
bolic syndrome do not exhibit increased circulating GC lev-
els. Thus, it has been suggested that metabolic syndrome
may result from increased intracellular GC tone, as may oc-
cur with elevated 11
 
 
 
-HSD1 activity, and that pharmaco-
logic inhibition of 11
 
 
 
-HSD1 may alter intracellular GC
levels and be therapeutic for metabolic syndrome (3–5).
Several recent experiments in mice support this hypoth-
esis. Overexpression of 11
 
 
 
-HSD1 in murine adipose leads
to a metabolic syndrome–like phenotype, including in-
creased central obesity, hypertension, impaired glucose tol-
erance, and hypertriglyceridemia (6, 7). These transgenic
mice have elevated intraadipose corticosterone levels but
normal circulating levels. Conversely, mice that fail to ex-
press 11
 
 
 
-HSD1 are resistant to the development of meta-
bolic syndrome (8, 9). 11
 
 
 
-HSD1 KO mice resist hypergly-
cemia provoked by obesity or stress, resist weight gain on
high-fat (HF) feeding, and have a cardioprotective lipid
phenotype, including elevated high density lipoprotein
(HDL) cholesterol and low triglyceride levels. This benefi-
cial phenotype occurs despite activation of the HPA axis in
these mice, which underscores that changes in intracellular,
rather than circulating, GC levels determine the metabolic
phenotype in mice.
Though the predominant source of morbidity and mor-
tality in metabolic syndrome is from atherosclerotic cardio-
vascular disease, the effect of 11
 
 
 
-HSD1 inhibition on
atherogenesis has not been studied. A potent and selective
nonsteroidal inhibitor of murine and human 11
 
 
 
-HSD1 was
dosed in murine models of diet-induced obesity (DIO) and
type 2 diabetes and a mouse model of atherosclerosis, the
apolipoprotein E (apoE) KO mouse. We report that phar-
macologic inhibition of 11
 
 
 
-HSD1 can ameliorate multiple
facets of metabolic syndrome as well as prevent atheroscle-
rotic lesion progression in these disease models.
 
RESULTS
Potency and pharmacodynamic (PD) activity of 
11
 
 
 
-HSD1 inhibitor
 
To examine the role of 11
 
 
 
-HSD1 in the etiology of meta-
bolic syndrome and to explore the role of 11
 
 
 
-HSD1 in ath-
erosclerotic plaque formation, we tested the effect of phar-
macologic inhibition of 11
 
 
 
-HSD1 using a novel potent and
selective nonsteroidal inhibitor in murine models of diabetes,
obesity, and atherosclerosis. Compound 544 (3-(1-adaman-
tyl)-6,7,8,9-tetrahydro-5
 
H
 
-[1,2,4]triazolo[4,3-
 
a
 
]azepine; Fig.
1 A) is a potent inhibitor of both mouse and human 11
 
 
 
-
HSD1 with 
 
 
 
100- or 
 
 
 
450-fold selectivity over mouse or
human 11
 
 
 
-HSD2, respectively (Fig. 1 A). The compound
is a competitive inhibitor for cortisone, but not NADPH,
suggesting that it interacts with the steroid binding site (un-
published data). The specificity of the inhibitor was assessed
in 
 
 
 
170 receptor binding and enzyme assays, and no activity
at concentrations 
 
 
 
10 
 
 
 
M was detected, including GC re-
ceptor binding.
A PD mouse model was used to evaluate the efficacy of
compound 544 in inhibiting 11
 
 
 
-HSD1 reductase activity in
the entire animal. Evidence from 11
 
 
 
-HSD1 KO mice sug-
gests that 11
 
 
 
-HSD1 is the only 11
 
 
 
 reductase in mice capa-
ble of converting inactive to active GC (8). 2 min of expo-
sure after i.v. administration of [
 
3
 
H]cortisone resulted in 58%
conversion to [
 
3
 
H]cortisol in the vehicle-treated ICR mice
(
 
n
 
 
 
 
 
 3 per time point). Oral administration of compound 544
at 10 or 30 mg/kg inhibited 11
 
 
 
 reductase activity at 1 h by 60
or 75%, respectively. For the higher dose, this effect dimin-
ished to 
 
 
 
30% by 4 h with essentially no inhibition by 16 h
(Fig. 1 B). Inhibitor administered at 10 mg/kg lowered en-
zyme activity by 
 
 
 
10% by 4 h and was ineffective by 12 h.
Serum measurements of cortisol elaboration in the PD
mouse model reflect the sum of inhibition occurring in the
various 11
 
 
 
-HSD1–expressing tissues. Cortisone adminis-
tered i.v. enters cells from the circulation, is converted by
11
 
 
 
-HSD1 to cortisol, and the cortisol, specifically labeled
Figure 1. Characteristics of the 11 -HSD1 inhibitor compound 
544. (A) Structure and in vitro potency of compound 544. Potency of 
compound 544 against human and murine 11 -HSD1 and -HSD2 was 
determined as described in Materials and methods. The IC50 was determined 
from  25 determinations for each enzyme. (B) PD activity of 11 -HSD1 
inhibitor in serum. Compound 544 was orally administered to mice and 
the percent inhibition of [3H]cortisone conversion to cortisol was measured 
relative to controls dosed with vehicle only. Data are a representative study 
of at least two experiments. Statistical significance is calculated between 
the treatment groups and vehicle controls (*, P   0.05; **, P   0.005). 
Values represent the mean   SEM. (C) PD activity of 11 -HSD1 inhibitor 
in key organs. Data are the mean of two experiments. Statistical signifi-
cance is calculated between the treatment groups and vehicle controls 
(*, P   0.05; **, P   0.005). Values represent the mean   SEM. 
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with tritium, reenters the circulation, where it is detected in
serum by HPLC. To understand the degree of 11
 
 
 
-HSD1
activity inhibition in specific organs of interest, the liver, ep-
ididymal fat, and brains from mice dosed with compound
544 at 30 mg/kg were excised, minced, and exposed to
[
 
3
 
H]cortisone ex vivo for 10 min (liver) or 2 h (epididymal
white adipose tissue [EWAT] and brain). The elaboration of
[
 
3
 
H]cortisol in the media can be dose-dependently inhibited
by compound 544 administration before death (Fig. 1 C).
Liver inhibition averaged 35% over the first 4 h after inhibi-
tor administration (30 mg/kg) and nearly disappeared by 6 h.
EWAT showed a similar time course of inhibition, whereas
inhibition in the brain was shorter lived and diminished to
low levels by 4 h.
 
11
 
 
 
-HSD1 inhibition decreases body weight gain, 
food intake, and fat pad weight in DIO mice
 
Inhibition of 11
 
 
 
-HSD1 lowers body weight and appetite
in DIO mice. The DIO mice (
 
n 
 
  
 
42) had an average body
weight of 45.1 
 
 
 
 0.5 g before dosing with compound 544
(vehicle control group: 
 
n 
 
  
 
41, 48.0 
 
 
 
 0.6 g). After 11 d of
dosing with 11
 
 
 
-HSD1 inhibitor at 20 mg/kg twice daily,
their body weights were reduced by 7% (P 
 
  
 
0.001),
whereas the body weight of the vehicle group was essen-
tially unchanged (Fig. 2, A and B). Dosing with compound
544 also affected the animals’ feeding behavior, resulting in
a 12.1% reduction in cumulative food intake compared
with the vehicle-treated animals (P 
 
  
 
0.001; Fig. 2 C). Fur-
thermore, compound 544 caused a preferential loss of cen-
tral fat pad weight, as there was a reduction of retroperito-
neal fat weight in DIO mice (
 
n 
 
  
 
24) compared with
vehicle-treated control animals (Fig. 2 D), but it essentially
had no effect on epididymal fat weight (Fig. 2 E). We did
not observe changes of 11
 
 
 
-HSD1 mRNA expression in
the liver or adipose after treatment of the DIO mice with
the inhibitor (unpublished data). Unlike the DIO mice, the
HF/streptozotocin (STZ) animals in our studies had only
slightly greater average body weights than controls (41 
 
 
 
1.3 g vs. 39 
 
  
 
1.9 g, respectively), and 11
 
 
 
-HSD1 inhibi-
tion had little effect (39 
 
 
 
 4 g for compound 544). Interest-
ingly, there was a statistically nonsignificant lowering of se-
rum leptin levels in the HF/STZ mice (5.88 
 
 
 
 1.1 ng/ml
for compound 544 vs. 9.6 
 
 
 
 2.3 ng/ml for vehicle [P 
 
 
 
0.17] and 3.1 
 
 
 
 0.5 ng/ml for chow/saline controls), de-
spite no decreases in average body weight (39 
 
 
 
 4 g for
compound 544 vs. 41 
 
 
 
 1.3 g for vehicle and 39 
 
 
 
 1.9 g
for chow/saline controls).
 
11
 
 
 
-HSD1 inhibition lowers fasting glucose and improves 
insulin resistance in murine models of type 2 diabetes
 
Inhibition of 11
 
 
 
-HSD1 improved insulin sensitivity, hy-
perglycemia, and other glycemic parameters in murine DIO
and HF/STZ models. 7–12-mo-old DIO C57BL/6J mice
on an HF diet from weaning were hyperglycemic and hy-
perinsulinemic (Fig. 3, A and B). 11
 
 
 
-HSD1 inhibition with
compound 544 for 11 d in DIO mice at 20 mg/kg per os
[PO], twice daily, lowered fasting serum glucose levels by
15% compared with vehicle-treated animals (P 
 
  
 
0.001; Fig.
3 A). Insulin levels were lowered below those in the lean
controls (P 
 
  
 
0.001; Fig. 3 B).
Figure 2. 11 -HSD1 inhibition decreases body weight gain, food 
intake, and fat pad weight in DIO mice. Compound 544–treated DIO 
mice (closed bars) were compared with obese animals dosed with vehicle 
(light hatched bars) and with lean controls (open bars). Animals treated 
with RU38486 served as positive controls (dark hatched bars). Compound 
544 lowers body weight gain (A and B), food intake (C), and retroperitoneal 
fat pad weight (D), but not epididymal fat pad weight (E). Data shown are 
representative (B) or the mean (A and C–E) of at least two studies. Body 
weight gain was calculated relative to the weight of each individual 
animal before initiation of compound treatment. Statistical significance 
is calculated between the treatment groups and vehicle controls (*, P   0.05; 
**, P   0.005). Values represent the mean   SEM. 
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The HF/STZ model manifests hyperglycemia, glucose
intolerance, insulin resistance, and a loss of insulin-secreting
 
 
 
 cells, all of which are characteristics of type 2 diabetes in
human patients (10). ICR mice are induced to develop dia-
betes through combined insulin resistance, induced by HF
feeding, and insulin deficiency, induced by a low dose of
STZ. These diabetic HF/STZ animals (
 
n 
 
  
 
17) were orally
dosed with the 11
 
 
 
-HSD1 inhibitor at 30 mg/kg twice
daily. Treated animals were compared with vehicle controls
(
 
n 
 
  
 
16) as well as to normoglycemic, normoinsulinemic
mice (chow/saline control; 
 
n   18) kept on a chow diet and
sham injected with saline instead of STZ. Compound 544
lowered fasting and postprandial glucose levels and improved
insulin sensitivity in HF/STZ animals after 9 d of oral dos-
ing. An oral or i.p. glucose tolerance test performed after an
overnight fast on day 9 of dosing revealed that the 11 -
HSD1 inhibitor lowered fasting glucose nearly to chow/
saline control levels (80% correction, P   0.001; Fig. 3 C) and
decreased the glucose serum excursions after glucose chal-
lenge by 29% (area under the curve correction calculated
relative to the difference between the HF/STZ vehicle and
chow/saline control; Fig. 3 D). The mean of two studies
dosed at 30 mg/kg bis in die ([BID]; P   0.02) is shown as a
representative experiment in Fig. 3 E. Postprandial glucose
levels for HF/STZ animals were significantly higher than
chow/saline control levels (P   0.001; Fig. 3 F) and were
lowered 37% relative to controls by inhibition of 11 -HSD1
(P   0.01). Insulin levels were also elevated in HF/STZ
animals (Fig. 3 G), though they were not as high as in the HF-
fed animals before partial   cell destruction by STZ treat-
ment (2.7   0.4 ng/ml). Treatment with the 11 -HSD1 in-
hibitor normalized these levels to the chow/saline control
values (P   0.01). Similarly, glucagon is elevated signifi-
cantly in the serum of HF/STZ animals, and compound 544
treatment reduced these levels to those of the control (P  
0.005; Fig. 3 H).
11 -HSD1 inhibition lowers serum lipids in murine models 
of metabolic syndrome or atherosclerosis
Inhibition of 11 -HSD1 activity improved lipid profiles in
our murine models. Compound 544 lowered serum triglyc-
erides in the HF/STZ, DIO, and apoE KO mice. It lowered
Figure 3. 11 -HSD1 inhibition lowers fasting glucose and improves 
insulin resistance in murine models of type 2 diabetes. Compound 
544 (closed bars and closed triangles) was administered twice daily by oral 
gavage to DIO obese mice (A and B) or HF/STZ mice (C–H). The effects were 
compared with affected animals that were dosed with vehicle (light hatched 
bars and open squares) and with unaffected lean or chow/saline controls 
(open bars and open diamonds). Animals treated with RU38486 served 
as a positive control (dark hatched bars). Compound 544 lowers fasting 
glucose (A, DIO and C, HF/STZ), serum insulin (B, DIO and G, HF/STZ), 
glucagon (H, HF/STZ), postprandial glucose (F, HF/STZ), and glucose excur-
sions after oral glucose challenge (D and E). Data shown are the mean of 
at least two studies. Statistical significance is calculated between the 
treatment groups and vehicle controls for DIO and between the treated 
groups and the difference between vehicle and chow/saline controls for 
HF/STZ (*, P   0.05; **, P   0.005). Values represent the mean   SEM.JEM VOL. 202, August 15, 2005 521
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free fatty acids in the HF/STZ model (the endpoint was not
examined in the other models) and cholesterol in the DIO
and apoE KO mice (not tested in HF/STZ). Triglyceride
levels were reduced by 18% in DIO mice compared with ve-
hicle-treated animals (P   0.002; Fig. 4 A). Serum choles-
terol levels were nearly doubled in DIO mice versus lean
controls, and 11 -HSD1 inhibition lowered serum choles-
terol by 24% (P   0.012; Fig. 4 B). Serum triglycerides were
increased by 1.75-fold in HF/STZ animals as compared with
chow/saline control levels, and 11 -HSD1 inhibitor treat-
ment abrogated this increase (96% correction, P   0.005;
Fig. 4 C). Serum-free fatty acids were increased in HF/STZ
animals, though the difference compared with chow/saline
controls was modest (P   0.05; Fig. 4 D). Nevertheless, 11 -
HSD1 inhibition significantly lowered free fatty acids (122%
correction, P   0.003). In apoE KO mice, inhibition of 11 -
HSD1 (10 mg/kg of compound 544 in feed for 8 wk begin-
ning at 16 wk of age; n   8) lowered circulating levels of
cholesterol by 28% (P   0.03; Fig. 4 F) and serum triglycer-
ides by 61% relative to vehicle controls (P   0.005; Fig. 4 E).
The GC (progesterone) receptor antagonist RU38486
(mifepristone) showed comparable effects to the 11 -HSD1
inhibitor in the HF/STZ and DIO mouse models (10 mg/
kg PO, twice daily; Figs. 2–4, dark hatched bars), further
suggesting that the effects of 11 -HSD1 inhibition are in-
deed obtained through a lessening of signaling through the
GC receptor. RU38486 lowered fasting glucose in both
models and improved insulin sensitivity and glucagon levels
in the HF/STZ mice. RU38486 lowered body weight, food
intake, and fat pad weights in the DIO mice and lowered tri-
glycerides in the HF/STZ animals. In vitro assays confirmed
that RU38486 lacked inhibitory activity against either
mouse or human 11 -HSD1 at concentrations  10   M
(unpublished data).
11 -HSD1 inhibition decreases aortic lesion area in a mouse 
model of atherosclerosis
11 -HSD1 inhibition not only improves cardiovascular dis-
ease risk factors such as insulin resistance, obesity, and dyslip-
idemia, but we show that it also dramatically slows plaque
progression in atherosclerotic lesions. Targeted deletion of
the apoE gene diminishes hepatic uptake of circulating cho-
lesterol and causes the development of aortic atherosclerotic
plaques in C57BL/6 mice on an atherogenic HF diet (11,
12). Such animals received compound 544 (10 mg/kg/day;
n   8) in the feed for 8 wk, beginning at 16 wk of age (base-
line). In the period from 16–24 wk of age, the untreated an-
imals tripled the amount of cholesterol deposited in aortic le-
sions (n   8; Fig. 5 A). Compound 544 almost completely
prevented this plaque progression (84% less total aortic cho-
lesterol; P   0.001; Fig. 5 A,). Aortic cholesterol ester, the
species of cholesterol that is found in atherosclerotic aortas,
but not normal aortas, showed a similar pattern of accumula-
tion (89% inhibition of accumulation with 11 -HSD1 inhi-
bition; P   0.05) as did free aortic cholesterol. There was no
significant effect of 11 -HSD1 inhibition on body weight in
the vehicle and compound 544–treated (10 mg/kg) groups
(36.5    2 g compared with 35   1.6 g, respectively),
whereas postprandial glucose levels were modestly decreased
in these two groups (302   20 mg/dL compared with t
166.8   23 mg/dL, respectively; P   0.001). Representa-
tive images of aortic arch specimens from apoE KO mice
show the diminution of lesion area with compound 544
treatment (Fig. 5 D compared with C [24-wk-old vehicle
controls] and B [16-wk-old baseline controls]). Although the
effect of 11 -HSD1 inhibition on serum lipids and glucose
may contribute to decreased atherosclerotic lesion progres-
sion, the extent of the effect appears disproportionate to
Figure 4. 11 -HSD1 inhibition lowers serum lipids in murine models 
of metabolic syndrome or atherosclerosis. Compound 544 (closed bars) 
was administered twice daily by oral gavage to DIO mice (A and B), HF/STZ 
mice (C and D), or apoE KO mice (E and F). The effects were compared with 
affected animals that were dosed with vehicle (light hatched bars) and 
with control animals (open bars). Controls included baseline 16-wk-old 
animals for apoE KO mice, lean animals for DIO mice, or chow/saline-
treated animals for HF/STZ mice. Animals treated with RU38486 served as 
a positive control for DIO and HF/STZ models (A–D, dark hatched bars). 
Compound 544 lowers triglycerides (A, DIO; C, HF/STZ; and E, apoE KO), 
serum cholesterol (B, DIO and F, apoE KO), and free fatty acids (D, HF/STZ). 
Data shown are the mean of at least two studies. Statistical significance is 
calculated between the treatment groups and vehicle controls for DIO, the 
treated groups and the difference between vehicle and chow /saline controls 
for HF/STZ, or the difference between vehicle and baseline controls for 
apoE KO (*, P   0.05; **, P   0.005). Values represent the mean   SEM.HSD1 INHIBITOR FOR ATHEROSCLEROSIS, SYNDROME X | Hermanowski-Vosatka et al. 522
these metabolic improvements and suggests an additional di-
rect effect of 11 -HSD1 inhibition on the artery wall. In-
deed, preliminary data show that serum levels of the proin-
flammatory cytokine monocyte chemoattractant protein
(MCP)–1 are lowered by compound 544 in these apoE KO
mice (vehicle group, 231   44 pg/ml vs. compound 544
group, 107   15 pg/ml; P    0.02). Further studies are
needed to completely elucidate the mechanism of the anti-
atherogenic effect of HSD1 inhibition.
DISCUSSION
Using recently defined diagnostic criteria (13), it has been
estimated that  20% of the adult population of the United
States has metabolic syndrome and that the incidence rises to
 40% of the population  60 yr of age (14). Metabolic syn-
drome exacts an enormous cost on Western societies, pri-
marily through a strong increase in the risk of atherosclerosis
and coronary heart disease. Given the seriousness of the car-
diovascular health threat posed by metabolic syndrome, the
third report of the National Cholesterol Education Program
recommended that physicians treat the disease aggressively,
even though the committee acknowledged that weapons at
the disposal of physicians are few and that, in the case of life-
style interventions such as weight loss and exercise, compli-
ance is poor. Given the difficulty in achieving lasting lifestyle
changes, an urgent need for pharmacologic intervention
clearly exists. However, the mechanisms by which the meta-
bolic syndrome affects heart disease are a long-standing
enigma. The experiments described here demonstrate a
novel pharmacologic means of controlling metabolic syn-
drome and curtailing the risk of atherosclerosis. They further
suggest a critical role for elevated intracellular cortisol levels
in the acceleration of atherosclerosis associated with meta-
bolic syndrome.
A recent prospective study in 714 nondiabetic adults sug-
gests that visceral obesity precedes the development of other
metabolic syndrome components, including insulin resistance
(15). Although patients with metabolic syndrome have nor-
mal circulating levels of GCs, it is still possible that local dys-
regulation of intracellular GC tone occurs in these patients
(16). An aberrantly high intracellular activation of GCs by
11 -HSD1 has indeed been noted in the adipose and skeletal
muscle of obese insulin-resistant humans (17–20). Experi-
mental manipulation of 11 -HSD1 activity in animal models
also points to the importance of intracellular GC tone in the
metabolic syndrome phenotype. Transgenic overexpression
of 11 -HSD1 in murine visceral fat or selective disruption of
the gene leads to a metabolic syndrome–like phenotype (6,
7), or confers protection from development of the metabolic
syndrome phenotype (8), respectively. Treatment of Zucker
rats with carbenoxolone, a nonspecific inhibitor of 11 -
HSD1 and -HSD2, led to inhibition of 11 -HSD1 in the
liver and concomitantly improved the lipid profile of the ani-
mals (21). Finally, recent studies with an arylsulfonamidothia-
zole class of an 11 -HSD1 inhibitor with  30-fold selectiv-
ity over 11 -HSD2 show improvement of insulin sensitivity
in diabetic mouse models (22, 23).
GCs regulate several inflammatory and metabolic func-
tions. Patients with Cushing’s syndrome develop central
obesity and a redistribution of adipose tissue away from sub-
cutaneous depots and into the visceral compartment. Fur-
thermore, GCs are orexigenic. Therefore, it is not surprising
that the lowering of GC tone via inhibition of 11 -HSD1
activity would lower body weight and food intake, as shown
here for the DIO mouse model. It is interesting to note that
treated animals lost more weight in the visceral, or retroperi-
toneal, depot than in the epididymal fat pad. Although the
mechanism for the fat redistribution effect of GCs has not
been completely elucidated, it is clear that different depots
vary in their degree of metabolic activity (24) and that,
therefore, a hormone that regulates metabolic function of
adipose tissue would have varying effects in these different
depots. Various groups have noted increased 11 -HSD1 ac-
tivity or expression in adipose tissue from obese human sub-
jects (17–19, 25, 26), but another has failed to see any differ-
ence (27). Given the effects of GCs on adipogenesis, one can
expect a therapeutic benefit for lower prereceptor genera-
tion of activated GCs in adipose tissue even in the absence of
an increase in that activity in obesity.
As part of the stress response, GCs mobilize fuel sources
to enable the organism to respond to the stressor. As such,
Figure 5. 11 -HSD1 inhibition decreases aortic lesion area in a 
mouse model of atherosclerosis. Compound 544 (A, closed bars) lowered 
aortic total or free cholesterol and cholesterol ester content in apoE-deficient 
mice to nearly baseline levels when compared with untreated controls 
(A, hatched bars). apoE KO animals killed at 16 wk represent the baseline 
lesion area at initiation of the study (A and B, open bars). Aortic arch lesions, 
visible as milky opacities in a normally translucent aortic wall, are visibly 
diminished in size on compound 544 treatment (D) when compared with 
untreated controls (C). Statistical significance is calculated between the 
treated animals and the difference between baseline animals and vehicle 
controls (*, P   0.05; **P,   0.005). Values represent the mean   SEM.JEM VOL. 202, August 15, 2005 523
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they increase hepatic gluconeogenesis and antagonize the ef-
fects of insulin, which decreases glucose utilization by cells
and leads to elevated circulating levels of glucose and insulin
resistance. 11 -HSD1 is expressed in the islets of Langerhans,
and activation of 11-dehydrocholesterol by 11 -HSD1 in
isolated islets inhibits insulin release, an effect that can be in-
hibited by carbenoxolone (28). GCs have been shown to de-
stroy   cells in the islets of HF-fed rats (29), and 11 -HSD1
expression and activity are increased in the islets of Zucker
diabetic fatty rats with   cell destruction (30). Lowering GC
levels by adrenalectomy or GC receptor antagonism can im-
prove hyperglycemia and insulin resistance (31–33). In the
diabetic models presented here, 11 -HSD1 inhibition had a
profound effect on fasting glucose. This is consistent with a
lowering of GC tone in the liver and a lessening of hepatic
gluconeogenesis. Compound 544 increased insulin sensitiv-
ity, as evidenced by the decreased serum glucose excursions
on glucose tolerance testing in the HF/STZ model, which is
also consistent with decreased GC tone, antagonizing the ef-
fects of insulin on glucose uptake in adipose tissue and skele-
tal muscle. With improvements in hyperglycemia, the ani-
mals also had lower circulating insulin and glucagon levels.
PPAR  agonists reduce the expression and activity of 11 -
HSD1 in adipose tissue (30, 34), and suggest that the benefi-
cial effect of PPAR  agonists on metabolic syndrome may, at
least in part, be caused by their ability to diminish GC pro-
duction by 11 -HSD1. RU38486 showed comparable ef-
fects to the 11 -HSD1 inhibitor, further suggesting that the
effects of 11 -HSD1 inhibition are indeed obtained through
a lessening of signaling through the GC receptor.
GCs are known to have multiple effects on lipid metabo-
lism. These hormones increase lipolysis in adipocytes and
regulate hepatic lipoprotein production such that patients
with Cushing’s syndrome have elevated serum-free fatty ac-
ids, triglycerides, and cholesterol. Inhibition of 11 -HSD1
caused the lowering of serum triglycerides in the HF/STZ,
DIO, and apoE KO mice. Free fatty acids were lowered in
the HF/STZ model and cholesterol was lowered in the DIO
and apoE KO mice. These data are also consistent with the
observation that 11 -HSD1 KO mice have a cardioprotec-
tive lipid phenotype (35). Finally, PPAR  agonists such as
fibrates are very effective agents for treating dyslipidemia and
have been shown to reduce 11 -HSD1 expression and ac-
tivity in murine liver (36).
The metabolic syndrome is associated with a dramatic in-
crease in the risk of coronary heart disease, the principal
source of morbidity and mortality in this syndrome (37, 38).
The data presented here thus suggest that inhibition of 11 -
HSD1 may be an effective means for lowering cardiovascular
risk in metabolic syndrome. The addition of compound 544
to the diet of apoE KO mice almost completely blocked
plaque progression. The degree of improvement in aortic
lipid content with 11 -HSD1 inhibition seems greater than
can be accounted for by the relatively modest lowering of
serum triglycerides, cholesterol, and postprandial glucose in
this model. The precise mechanism for this beneficial effect
of lowered GC tone on the artery wall is unclear. We know
that the cells of the artery wall, specifically macrophages,
smooth muscle, and endothelial cells, which are also present
in atherosclerotic plaques, express 11 -HSD1 activity (39–
41). Treatment of aortic rings with antisense oligonucle-
otides against 11 -HSD1 attenuated the contractile response
to phenylephrine (42). Lowering vessel wall and intraplaque
production of an antiinflammatory hormone such as cortisol
by inhibiting 11 -HSD1 might be expected to exacerbate
rather than slow the progression of atherosclerotic disease.
However, our investigations into the inflammatory state of
the apoE mice show that circulating levels of the proinflam-
matory cytokine MCP-1 are decreased with 11 -HSD1 in-
hibition. Furthermore, preliminary efforts to profile gene
expression in the aortic plaques of 11 -HSD1 inhibitor–
treated apoE KO mice reveal that aortic MCP-1 expression
is lowered by inhibitor treatment. Gene signatures from
primary human aortic smooth muscle cells treated with 11 -
HSD1 inhibitor in culture also reveal decreases in proin-
flammatory gene expression (Luo, M.-J., personal commu-
nication). We intend to follow up on these preliminary
observations that 11 -HSD1 inhibitors act to slow plaque
progression through a direct antiinflammatory effect on vas-
cular cells in order to understand the relative contribution of
lowering serum lipids versus an antiinflammatory effect at
the vessel wall. Although this antiinflammatory and athero-
protective effect of lowering GC production may seem sur-
prising, it is not without precedent. Studies on Cushing’s
disease patients one year after remission and normalization of
GC levels show considerably decreased intimal medial thick-
ness of the carotid wall by ultrasound as well as notable in-
creases in carotid systolic lumen diameter and distensibility
coefficient, with only relatively modest improvements in
body weight, hyperglycemia, and dyslipidemia (43). Experi-
ments are underway to more completely characterize the ef-
fects of 11 -HSD1 inhibition on the inflammatory status of
the apoE KO mice and on the expression profile of the key
cells of the atherosclerotic lesion, using in situ approaches,
such as laser capture microdissection of plaques from animals
treated with inhibitor, as well as in vitro approaches, such as
exposure of vascular cells to 11 -HSD1 inhibitors in culture.
There is ample data in the literature to suggest that the
categorization of GCs as purely antiinflammatory hormones
may be an oversimplification. Physiologists studying adrenal-
ectomized animals in the early 20th century determined that
GCs were a necessary part of a coordinated response to stress
or injury, and it was only after these hormones were purified
and administered at high doses that their potent antiinflam-
matory actions were discovered. Studies performed at GC
concentrations closer to the basal, unstimulated state reveal
GC-mediated enhancement of such diverse inflammatory
processes as hepatic acute phase response, delayed-type hy-
persensitivity response, inflammatory cell cytokine secretion,
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the proinflammatory mediator macrophage migration inhib-
itory factor (44, 45). For example, GCs have been shown to
increase the expression of proinflammatory receptors in
macrophages (TLR4, IL1R, TNFR, etc.) and to enhance
immune responses such as the delayed type hypersensitivity
response (46, 47). Gene profiling of human peripheral blood
mononuclear cells has shown that GCs can regulate some
genes in opposite directions, depending on the activation
state of the target cells (47). These data suggest a highly com-
plex regulatory role of GC in human immune functions.
It has been difficult to quantify a relationship between
the metabolic syndrome risk factors and atherosclerosis as a
means of assessing risk because the extent of risk appears
greater than the sum of the individual parts For instance, the
4-yr risk of incident myocardial infarction among men from
age 40 to 65 in the Prospective Cardiovascular Münster
study was increased 2.5 times in the presence of either type 2
diabetes or hypertension, 8 times in the presence of both fac-
tors, and 19 times in the presence of both factors plus an ab-
normal lipid profile (48). Our observations suggest an expla-
nation for these findings. We propose that the mechanistic
contributors to atherosclerotic disease are not drawn only
from the short list of known risk factors (hyperlipidemia, in-
sulin resistance, and hypertension) but from other processes
as well. We have shown that lowering intracellular GC pro-
duction by HSD1 inhibition can be antiinflammatory, low-
ering circulating levels of the proinflammatory cytokine
MCP-1. Our results suggest that excess GCs are a candidate
for the underlying dysregulation that generates a host of con-
ditions that in turn contribute synergistically to atherogene-
sis. In keeping with this notion, Kumari et al. (49) have
shown that chronic mild stress can induce or accelerate the
development of atherosclerosis in the apoE-deficient mouse.
We propose that excess intracellular GCs cause atherogenesis
through a broad network of physiologic responses to this
protean hormone.
Because 11 -HSD1 is expressed in the hypothalamus
and pituitary and adrenal glands, 11 -HSD1 inhibition
would be expected to affect the function of the HPA axis.
Indeed, 11 -HSD1 KO mice have evidence of altered HPA
feedback, including elevated corticosterone at nadir and ad-
renal hyperplasia (8). Although circulating GCs are slightly
elevated, mice lacking 11 -HSD1 have no signs of Cush-
ing’s disease–like symptoms such as fat redistribution or insu-
lin resistance, and they reproduce normally and have appar-
ently normal behavioral reactions to fasting, acute restraint
stress, and forced swimming (8, 35, 50). Pharmacologic inhi-
bition of 11 -HSD1 did not affect the terminal circulating
corticosterone levels in serum for any of the models used
here (DIO model: vehicle, 101.4   12.1 ng/ml vs. com-
pound 544, 80.9   12.2 ng/ml; HF/STZ model: vehicle, 96  
24 ng/ml vs. compound 544, 95   26 ng/ml; and apoE / 
model: vehicle, 82   11 ng/ml vs. compound 544, 71  
9 ng/ml). This lack of effect, although not examined rigor-
ously in our experiments, suggests that partial pharmacologic
inhibition of 11 -HSD1 is sufficient to have beneficial ef-
fects and may not be enough to measurably alter HPA func-
tion. In additional studies, DIO mice chronically dosed with
11 -HSD1 inhibitor were subjected to restraint stress. These
mice showed considerable reductions in body weight and
improvement in insulin sensitivity with no changes in adre-
nal or thymus weights and no changes in basal or restraint-
induced elevations in corticosterone or adrenocorticotropic
hormone (unpublished data). These data suggest that inhibi-
tion of 11 -HSD1 at levels sufficient to give beneficial met-
abolic effects does not have deleterious effects on the capac-
ity of the HPA axis to respond to a standard stressor.
In summary, our data support the notion that the inhibi-
tion of 11 -HSD1 can be beneficial in metabolic syndrome
and atherosclerotic disease. These studies used a potent and
specific adamantyl-triazole inhibitor of 11 -HSD1 with
good in vitro and in vivo efficacy. This 11 -HSD1 inhibi-
tor, compound 544, improved insulin resistance and glucose,
insulin, and glucagon levels in mouse models of type 2 dia-
betes and obesity. 11 -HSD1 inhibition also lowered body
weight and central fat pad mass and improved dyslipidemia
in mouse models of obesity, diabetes, or atherosclerosis.
Most strikingly, the 11 -HSD1 inhibitor almost completely
prevented atherosclerotic plaque progression in the apoE
KO, a mouse model of atherosclerosis. Metabolic features
such as hyperglycemia (51, 52) and vessel wall abnormalities
(43) are reversible in treated Cushing’s disease patients, sug-
gesting that humans, like mice, will benefit from lowering
11 -HSD1 activity and, thus, active GC generation in key
metabolic organs.
MATERIALS AND METHODS
Reagents. All reagents were obtained from Sigma-Aldrich unless other-
wise stated.
11 -HSD1 inhibitor. Compound 544 (3-(1-adamantyl)-6,7,8,9-tetrahy-
dro-5H-[1,2,4]triazolo[4,3-a]azepine) was dosed by oral gavage in either 5%
hydroxypropyl- -cyclodextrin (for activity measurements) or in 0.5% meth-
ylcellulose containing 5% Tween 80 (in disease models). A direct compar-
ison of the two vehicles shows that compound 544 administered in either
vehicle yields comparable results on enzyme activity inhibition. For the
apoE KO mouse model, compound 544 was administered in the feed.
Animal husbandry. All experimental animal procedures were approved
by the Institutional Animal Care and Use Committee of Merck Research
Laboratories. Unless otherwise stated, all animals were maintained under
controlled conditions of 25 C and 12-h light/dark cycles (7:00 a.m./7:00
p.m.), with food and water available ad libitum. Twice daily dosing oc-
curred at  9:00 a.m. and 5:00 p.m.
Measurement of 11 -HSD1 and -HSD2 activity in vitro. In vitro
enzyme assays were performed with a 100,000-g membrane fraction of a
postnuclear supernatant from Chinese hamster ovary cells (CHO-K1; Amer-
ican Type Culture Collection) stably transfected with an expression vector
(pcDNA3.1; Invitrogen) encoding human or murine 11 -HSD1 or -HSD2
and 20 nM [3H]cortisone (11 -HSD1 reductase assay; American Radiola-
beled Chemical) or [3H]cortisol (11 -HSD2 dehydrogenase assay; GE
Healthcare) with 1 mM cofactor (NADPH or NAD, respectively). Anticor-
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A–coated yttrium silicate; GE Healthcare) were used to capture [3H]cortisol
generated in or remaining from the enzyme reaction. CHO-K1 cells trans-
fected with the control vector lack both enzyme activities (unpublished
data). Percent inhibition was calculated relative to a noninhibited control.
Measurement of 11 -HSD1 activity in vivo. Compound 544 was dosed
orally in three 13-wk-old ICR male mice (Taconic Farms) per group on a stan-
dard chow diet (7012; Harlan Teklad) using 5% hydroxypropyl- -cyclodex-
trin as vehicle. After compound administration, animals were either challenged
with an i.v. bolus of tritiated cortisone, whose generation by 11 -HSD1
was measured by detection of circulating levels (serum PD assay), or tissues
were isolated and exposed to tritiated cortisone ex vivo (tissue PD assay).
For the serum PD assay, 0.2 ml [3H]cortisone in saline was injected i.v.
by tail vein at 3.3  M for a 20 nM final dose in a 35-g mouse, assuming a
distribution over total body water of 25 ml. The animal was killed 2 min af-
ter administration of substrate, and blood was drawn by cardiac puncture
into clotting tubes. The time of administration was previously determined
to be within linearity of the in vivo 11  reductase reaction and resulted in
recovery of 75% of radioactivity (unpublished data). Steroids were extracted
from 200  l of serum with 5 vol of ethyl acetate. Samples were air dried
and resuspended in 200  l of 16  g/ml of unlabeled cortisone/cortisone
(wt/wt   1:1) and subsequently analyzed by HPLC using a C18 column
(Inertsil; Phenomenex). The relative levels of [3H]cortisone and its reduced
product, [3H]cortisol, were determined for the compound- and vehicle-
dosed control groups by radiochromatography. The percent conversions of
[3H]cortisone to [3H]cortisol, as well as the percentage of inhibition, were
calculated as the ratio of the peak area for cortisol over the combined peak
areas for cortisone and cortisol. Other peaks constituted  15% of the total.
For tissue PD assay, EWAT, liver, and brain were removed and minced
into 2–3-mm pieces in RPMI 1640 with 5% FCS (Sigma-Aldrich) and 15
mM Hepes (GIBCO), and 50 U/ml penicillin–streptomycin (GIBCO
BRL) containing 20 nM [3H]cortisone. The total volume (in milliliters)
added was equivalent to approximately five times the mass of tissue (in mil-
ligrams). Tissue was then incubated at 37 C in a 5% CO2 atmosphere for 10
min (liver) to 2 h (brain and EWAT). Cortisol content of the supernatant
was determined by scintillation proximity assay.
DIO model. 6–10-mo-old C57BL/6J male mice (The Jackson Labora-
tory) were fed on an HF diet (34% fat by weight with 60% kcal from fat;
97070; Harlan Teklad) from week 4, and water was given ad libitum. The
animals were housed individually in cages and adjusted to the dosing regi-
men by vehicle administration (10% Tween 80 in 0.5% Methocel) 7 d be-
fore the initiation of treatment. 20 mg/kg 11 -HSD1 inhibitor, 25 mg/kg
of RU38486, or vehicle was administered by oral gavage (PO) twice daily
(BID), with one dose given in the morning and the other dose given in the
afternoon. The food intake and weight of the animals were recorded daily.
The treatments were resumed for 11 d, and the last dose was given in the
afternoon before termination of the study. Food was withdrawn from the
mice 4 h before death.
HF/STZ model. 4-wk-old male ICR mice (Taconic Farms) were fed an
HF diet (36% fat by weight with 58.4% kcal from fat; D00031501; Re-
search Diets Inc.) for 3 wk to generate peripheral insulin resistance, fol-
lowed by a single injection of 90 mg/kg of body weight of freshly prepared
STZ to induce partial   cell dysfunction. 4 wk after administration of STZ,
animals (n   8) on an HF diet ad libitum and housed 3–4 per cage were
dosed for 9 d with 11 -HSD1 inhibitor (30 mg/kg BID in 0.5% methylcel-
lulose and 5% Tween 80), RU38486 (10 mg/kg BID), or vehicle alone,
with one dose given in the morning and the other dose given in the after-
noon. A group of mice fed a chow diet and injected with saline instead of
STZ served as controls (chow/saline controls). Two other groups consisting
either of animals fed a chow diet and injected with STZ or of HF-diet ani-
mals injected with vehicle were used to monitor the contribution of STZ or
an HF diet to the development of diabetes (unpublished data).
apoE KO mouse model. C57BL/6 male apoE KO mice (The Jackson
Laboratory) were weaned at 4 wk of age onto an atherogenic Western diet
containing 21% fat and 0.15% cholesterol (88137; Harlan Teklad). At 16 wk
of age, mice were separated into the following treatment groups: Western
diet only (vehicle) or Western diet containing 0.01% 11 -HSD1 inhibitor
(equivalent to  10 mg/kg/day). After 8 wk of treatment, mice were killed,
serum was collected, and aortas were dissected from the aortic root to the
right renal artery for cholesterol extraction. Aortic lesions were quantitated
by measuring total cholesterol, free cholesterol, and cholesterol ester incor-
porated into the vessel, as previously described (53). Samples were collected
from 16-wk-old mice on an atherogenic diet to establish baseline control
levels of aortic and serum lipid. It should be noted, however, that murine
cholesterol profiles are quite distinct from those seen in humans. Circulating
cholesterol is found almost exclusively as HDL particles, whereas humans
have more low density lipoprotein than HDL. apoE deficiency renders yet
another, distinct lipoprotein profile in these mice, where chylomicrons and
very low density lipoprotein comprise the dominant population of particles.
Serum measurements. Overnight fasting and postprandial blood glucose
levels were detected by a glucometer (One Touch; LifeScan, Inc.) for the
HF/STZ model. Serum glucose levels were determined spectrophotometri-
cally by the hexokinase method (Hitachi 911; Roche Molecular Biochemi-
cals). Serum levels of insulin and leptin were measured by ELISA (Alpco).
Serum cholesterol levels were measured by cholesterol and triglyceride assay
kits (439-17501 and 997-37492; Wako Chemicals). Serum levels of triglyc-
erides and free fatty acids levels were quantified by a colorimetric diagnostic
kit (Roche Molecular Biochemicals).
Statistics. A two-factor linear model with analysis of variance was used to
account for interstudy variability for endpoints. All comparisons used P  
0.05 to claim statistically significant differences. The logarithmic scale was
used to better satisfy assumptions of normality and constant variance and to
naturally express comparisons as percent differences. All calculations were
performed in the R software environment (http://www.r-project.org).
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